Investment analysts at Truist Financial began coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. A number of other research analysts have also recently commented on PRAX. Jefferies […]